News:Wuhan Benjamin Pharmaceutical Chemical Co.,Ltd!
Product Type
Wuhan BJM Pharm Inc.
Add: No .41 Optics Valley Avenue, East Lake High-tech Development Zone, Wuhan ,China
Tel:+86-27-50661278 ；+86-27-52341919 ；+86-27-50661279；+86-52341789
E-mail:hr@benjaminpharmchem.com
APIYour current location: Home|Product
Product Name:Apremilast
Product number:BJM-041
CAS:608141-41-9
Molecular formula:
Molecular weight:460.5
Content:99.0%min
Picture:
Product number:BJM-041
CAS:608141-41-9
Molecular formula:
C22H24N2O7S
Molecular weight:460.5
Content:99.0%min
Apremilast / CAS No: 608141-41-9
Name: Apremilast
CAS No: 608141-41-9
Alisa: Apremilast (CC-10004) ; Otezla
MF: C22H24N2O7S
MW: 460.50
Description:
It's white powder
Density: 1.382 g/cm3
Boiling point: 741.342 °C at 760 mmHg
Flash point: 402.149 °C
Boiling point: 741.342 °C at 760 mmHg
Flash point: 402.149 °C
Assay:99.0%min
Usage: Anti psoriatic arthritis ; PDE4 and TNF alpha inhibitors
Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis.Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.
Picture:
